XML 13 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Cover - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Mar. 24, 2025
Jun. 30, 2024
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Document Transition Report false    
Entity File Number 001-40544    
Entity Registrant Name Aerovate Therapeutics, Inc.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 83-1377888    
Entity Address, Address Line One 930 Winter Street    
Entity Address, Address Line Two Suite M-500    
Entity Address, City or Town Waltham    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02451    
City Area Code 617    
Local Phone Number 443-2400    
Title of 12(b) Security Common stock, par value $0.0001 per share    
Trading Symbol AVTE    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period true    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction Flag false    
Entity Shell Company false    
Entity Public Float     $ 23.0
Entity Common Stock, Shares Outstanding   28,985,019  
Documents Incorporated by Reference

The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2025 Annual Meeting of Stockholders within 120 days of the end of the registrant’s fiscal year ended December 31, 2024. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.

    
Auditor Firm ID 185    
Auditor Name KPMG LLP    
Auditor Location San Diego, California    
Entity Central Index Key 0001798749    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Amendment Flag false